171 related articles for article (PubMed ID: 23833047)
1. What costs matter? Rethinking social costs of new device technologies.
Choby AA; Clark AM
Europace; 2013 Nov; 15(11):1538-9. PubMed ID: 23833047
[No Abstract] [Full Text] [Related]
2. Yes to cardiac devices. But at what cost?
Leyva F
Europace; 2013 Mar; 15(3):313-4. PubMed ID: 23243130
[No Abstract] [Full Text] [Related]
3. Cost-of-illness study of patients subjected to cardiac rhythm management devices implantation: results from a single tertiary centre.
Fanourgiakis J; Simantirakis E; Maniadakis N; Kourlaba G; Kanoupakis E; Chrysostomakis S; Vardas P
Europace; 2013 Mar; 15(3):366-75. PubMed ID: 23148117
[TBL] [Abstract][Full Text] [Related]
4. Infections and associated costs following cardiovascular implantable electronic device implantations: a nationwide cohort study.
Clémenty N; Carion PL; Léotoing L; Lamarsalle L; Wilquin-Bequet F; Brown B; Verhees KJP; Fernandes J; Deharo JC
Europace; 2018 Dec; 20(12):1974-1980. PubMed ID: 29672690
[TBL] [Abstract][Full Text] [Related]
5. Making the Most of Cardiac Device Remote Management: Towards an Actionable Care Model.
Diamond J; Varma N; Kramer DB
Circ Arrhythm Electrophysiol; 2021 Mar; 14(3):e009497. PubMed ID: 33657833
[No Abstract] [Full Text] [Related]
6. Clinical and organizational management of cardiac implantable electronic device replacements: an Italian Survey promoted by AIAC (Italian Association of Arrhythmology and Cardiac Pacing).
Palmisano P; Ziacchi M; Belotti G; Rapacciuolo A; Santini L; Stabile G; Zoni Berisso M; De Ponti R; Landolina M; Ricci RP; Boriani G;
J Cardiovasc Med (Hagerstown); 2019 Aug; 20(8):531-541. PubMed ID: 31259858
[TBL] [Abstract][Full Text] [Related]
7. Cardiac Pacing and Defibrillation Devices: Cost and Effectiveness.
Groeneveld PW; Dixit S
Annu Rev Med; 2017 Jan; 68():1-13. PubMed ID: 27686020
[TBL] [Abstract][Full Text] [Related]
8. Healthcare Utilization and Expenditures Associated With Appropriate and Inappropriate Implantable Defibrillator Shocks.
Turakhia MP; Zweibel S; Swain AL; Mollenkopf SA; Reynolds MR
Circ Cardiovasc Qual Outcomes; 2017 Feb; 10(2):. PubMed ID: 28196927
[TBL] [Abstract][Full Text] [Related]
9. Cardiac electrophysiology in Lebanon.
Refaat M; Khoury M
Heart Rhythm; 2010 Dec; 7(12):1914. PubMed ID: 21040806
[No Abstract] [Full Text] [Related]
10. Application of new pacemaker and defibrillator technology.
Shepard RB; Epstein AE; Kay GN
Adv Card Surg; 1994; 5():181-208. PubMed ID: 8118592
[No Abstract] [Full Text] [Related]
11. Implantation and patient profiles for pacemakers and cardioverter-defibrillators in France (2008-2009).
Tuppin P; Neumann A; Marijon E; de Peretti C; Weill A; Ricordeau P; Danchin N; Allemand H
Arch Cardiovasc Dis; 2011 May; 104(5):332-42. PubMed ID: 21693370
[TBL] [Abstract][Full Text] [Related]
12. New device indications: practice and cost implications in Europe.
Morgan JM; ;
Card Electrophysiol Rev; 2003 Jan; 7(1):49-53. PubMed ID: 12766518
[TBL] [Abstract][Full Text] [Related]
13. Cardiac electrophysiology: a cost-effective approach.
DiMarco JP
Clin Cardiol; 1996 Jul; 19(7):575-8. PubMed ID: 8818439
[TBL] [Abstract][Full Text] [Related]
14. Summaries for patients. The cost-effectiveness of cardiac resynchronization therapy for heart failure.
Ann Intern Med; 2004 Sep; 141(5):I29. PubMed ID: 15353442
[No Abstract] [Full Text] [Related]
15. Current state of the art for use of pacemakers and defibrillators in patients with congenital cardiac malformations.
Stephenson EA; Kaltman JR
Cardiol Young; 2006 Sep; 16 Suppl 3():151-6. PubMed ID: 17378055
[No Abstract] [Full Text] [Related]
16. Expansion of heart failure device therapy into a rural indigent population in Louisiana: potential economic and health policy implications.
Hebert K; McKinnie J; Horswell R; Arcement L; Stevenson L
J Card Fail; 2006 Dec; 12(9):689-93. PubMed ID: 17174229
[TBL] [Abstract][Full Text] [Related]
17. Recommendations from the Heart Rhythm Society Task Force on Device Performance Policies and Guidelines Endorsed by the American College of Cardiology Foundation (ACCF) and the American Heart Association (AHA) and the International Coalition of Pacing and Electrophysiology Organizations (COPE).
Carlson MD; Wilkoff BL; Maisel WH; Carlson MD; Ellenbogen KA; Saxon LA; Prystowsky EN; Alpert JS; Cain ME; Ching EA; Curtis AB; Davies DW; Hammill SC; Hauser RG; Lampert R; Zipes DP; ; ;
Heart Rhythm; 2006 Oct; 3(10):1250-73. PubMed ID: 17018366
[No Abstract] [Full Text] [Related]
18. Pharmacoeconomic considerations in antiarrhythmic therapy.
Podrid PJ; Arnold RJ; Kaniecki DJ
Pharmacoeconomics; 1992 Dec; 2(6):456-67. PubMed ID: 10147006
[TBL] [Abstract][Full Text] [Related]
19. Statistics on the use of cardiac electronic devices and electrophysiological procedures in 55 ESC countries: 2013 report from the European Heart Rhythm Association (EHRA).
Arribas F; Auricchio A; Boriani G; Brugada J; Deharo JC; Hindriks G; Kuck KH; Merino JL; Vardas P; Wolpert C; Zeppenfeld K
Europace; 2014 Apr; 16 Suppl 1():i1-78. PubMed ID: 24755466
[No Abstract] [Full Text] [Related]
20. Pacing in perspective: concepts and controversies.
Parsonnet V; Bernstein AD
Circulation; 1986 Jun; 73(6):1087-93. PubMed ID: 3516446
[No Abstract] [Full Text] [Related]
[Next] [New Search]
